Skip to main content
padlock icon - secure page this page is secure

Modulation of Innate Immune Responses in the Treatment of Sepsis and Pneumonia

Buy Article:

$68.00 + tax (Refund Policy)

In the last decades several preclinical models for sepsis have been used to study the pathophysiologic processes during sepsis. Although these studies revealed promising immunomodulating agents for the treatment of sepsis, clinical trials evaluating the efficacy of these new agents in septic patients were disappointing. It should be realized that most of the preclinical models for sepsis lack a localized infectious source from which the infection disseminates. Studies on the effects of several immunomodulating strategies have demonstrated strikingly opposite results when using models for sepsis with a more natural route of infection, such as pneumonia, and when using models for sepsis lacking an infectious focus. In this review we will compare models for sepsis and models for pneumonia. We advise to use a combination of models, including models for sepsis and models for localized infections, to test new immunomodulating strategies before starting any clinical trial evaluating a new immunomodulating therapy.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: cytokines; immunomodulation; innate immunity; pneumonia; sepsis

Document Type: Review Article

Affiliations: Dept. of Intensive Care Medicine, G3-206, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands;

Publication date: March 1, 2004

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more